BioNTech's Exciting Corporate Evolution Continues with the Appointment of Ramón Zapata as CFO

German biotechnology giant BioNTech has amped up its top-tier team by appointing accomplished finance executive Ramón Zapata as their Chief Financial Officer, taking the reins from July 1, 2025. In his vast career sprawled over 25 years, he has acquired substantial financial expertise and established his mark in global companies such as Novartis AG, Sandoz AG, and Mondelēz International.

Zapata’s addition to the BioNTech team is seen as a critical step in the company’s ongoing journey to evolve into a multi-product giant in the oncology sector. As the CFO, he will be responsible for developing a robust financial structure that will continue to be in sync with BioNTech’s strategic aims. His role will be paramount in fostering an environment of organisational excellence and driving cost-effective value creation through astute financial reporting, accounting, procurement, tax and treasury operations.

The chairman of the Supervisory Board, Helmut Jeggle, expressed his gratitude towards the outgoing CFO, Jens Holstein, for his incredible diligence and numerous contributions in maintaining the company’s financial stability and augmenting its operational efficiency. Holstein’s efforts have positioned BioNTech on a path of success, propelling it to become a global biotechnology powerhouse.

In turn, Holstein used his farewell to thank his teams for their tireless work and collaboration. He expressed a keen interest in focusing on non-executive Board roles in the future.

BioNTech’s new CFO, Ramón Zapata, exuded enthusiasm in joining the esteemed team. He is eager to carry forward the revolutionary vision of transforming patients’ lives by providing innovative and accessible medicinal solutions. His appointment symbolizes a significant stride for BioNTech as it continues to innovate in the field of oncology and aim to boost patients’ lives worldwide.